← All tickers

Is RLAY Worth Buying in 2026?

Relay Therapeutics, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-05-03

Here’s whether Relay Therapeutics, Inc. Common Stock (RLAY) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+10.71% over 10 days); strong 1-year return of +286.6%; 3-month momentum positive (+56.1%). Currently 26.6% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

RLAY is in a confirmed uptrend, trading above both its 50-day ($11.87) and 200-day ($7.62) moving averages. An RSI of 34.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +286.6% compares to +22.9% for SPY (beat the market by 263.8%). The current 26.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $38,663 today
vs. S&P 500 (SPY) — same period beat market by 263.8%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($7.62)
✓Above 50-day MA ($11.87)
✓RSI(14) neutral zone (30–70) — currently 34.5
✓Positive return (+286.6%)
!Within 10% of period high (−26.6%)
Period Range $12.72
$2.67 $17.32
RSI (14) 34.5
0 · OversoldOverbought · 100

Key Metrics

Price$12.72
Period Return+286.6%
Period High$17.32
Period Low$2.67
Drawdown−26.6%
MA-50$11.87
MA-200$7.62
RSI (14)34.5
Avg Volume (30d)3.4M
vs. SPYbeat by 257.6%
Return Rank#63 of 1246

Trade RLAY

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers